Investor Presentaiton
Company overview
Financial performance
Oncology
Financial review
2022 priorities
Appendix
Innovation: Pipeline overview
Innovation: Clinical trials
Immunology
Ophthalmology
Neuroscience
Respiratory Disease
sabatolimab - TIM3 antagonist
NCT04150029 STIMULUS-AML1 (CMBG453C12201)
Indication
Unfit acute myeloid leukaemia
Phase 2
Phase
Patients
86
Primary
Outcome
Measures
Arms
Intervention
Incidence of dose limiting toxicities (Safety run-in patients only)
Percentage of subjects achieving complete remission (CR)
Single arm safety and efficacy study of sabatolimab in combination with
azacitidine and venetoclax
Target
Patients
Newly diagnosed adult AML patients who are not suitable for treatment with
intensive chemotherapy
Read-out
Milestone(s)
2023
Publication
TBD
References
Abbreviations
Cardio-Renal
Global Health
Biosimilars
61 Investor Relations | Q2 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation